Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.97 USD | +6.93% |
|
+9.01% | +15.62% |
Jun. 25 | Oppenheimer Initiates Keros Therapeutics at Outperform With $102 Price Target | MT |
Jun. 18 | Keros Therapeutics Names Chief Executive Officer Jasbir Seehra as Board Chair | MT |
Business Summary
Number of employees: 141
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Therapeutics for Hematological, Pulmonary and Cardiovascular Disorders
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jasbir Seehra
CEO | Chief Executive Officer | 68 | 15-11-30 |
President | 50 | 22-01-31 | |
Keith Regnante
DFI | Director of Finance/CFO | 54 | 20-01-31 |
Jennifer Lachey
CTO | Chief Tech/Sci/R&D Officer | 51 | 16-06-30 |
Justin Frantz
IRC | Investor Relations Contact | - | - |
Robin Wagner
HRO | Human Resources Officer | - | 21-05-31 |
Esther Cho
LAW | General Counsel | - | 20-03-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Mary Gray
BRD | Director/Board Member | 71 | 20-12-16 |
Carl Gordon
BRD | Director/Board Member | 59 | 20-02-29 |
Jasbir Seehra
CEO | Chief Executive Officer | 68 | 15-11-30 |
Tomer Kariv
BRD | Director/Board Member | 62 | 19-12-31 |
Ran Nussbaum
BRD | Director/Board Member | 51 | 16-03-31 |
Nima Farzan
BRD | Director/Board Member | 48 | 20-02-29 |
Julius Knowles
BRD | Director/Board Member | 61 | 16-03-31 |
Alpna Seth
BRD | Director/Board Member | 60 | 23-04-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 36,083,886 | 33,884,264 ( 93.90 %) | 0 | 93.90 % |
Company contact information
![address Keros Therapeutics, Inc.(KROS)](https://cdn.zonebourse.com/static/address/106001599.png)
Sector
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.62% | 1.55B | |
+20.95% | 127B | |
+23.00% | 116B | |
+25.15% | 27.69B | |
-19.75% | 19.62B | |
-16.57% | 16.26B | |
-16.56% | 15.49B | |
+11.19% | 14.81B | |
-46.65% | 14.39B | |
+57.74% | 14.11B |
- Stock Market
- Equities
- KROS Stock
- Company Keros Therapeutics, Inc.